VBI Vaccines Announces Dosing of First GBM Patient in Phase 1/2a Clinical Study of VBI-1901
17 janv. 2018 08h00 HE
|
VBI Vaccines, Inc.
Two-part Phase 1/2a study of VBI-1901 to enroll patients with recurrent GBM Part A: Dose escalation to enroll up to 18 patientsPart B: Subsequent extension of optimal dose to enroll up to 10...
VBI Vaccines to Present at the BMO Capital Markets 2017 Prescriptions for Success Healthcare Conference
12 déc. 2017 08h00 HE
|
VBI Vaccines, Inc.
CAMBRIDGE, Mass., Dec. 12, 2017 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (Nasdaq:VBIV) (TSX:VBV) (VBI) today announced that Jeff Baxter, President and CEO, will present at the BMO Capital Markets...
VBI Vaccines to Present New Preclinical Data for its GBM Immunotherapy, VBI-1901, at SITC 2017
10 nov. 2017 08h00 HE
|
VBI Vaccines, Inc.
New data confirms use of intradermal delivery of eVLPs may be a potent “off-the-shelf” immunotherapy vaccinePoster presentation at the Society for Immunotherapy of Cancer’s (SITC) 32nd Annual Meeting...
VBI Vaccines Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares and Upsized Registered Direct Offering for Aggregate Proceeds of $71.9 Million
30 oct. 2017 08h00 HE
|
VBI Vaccines, Inc.
CAMBRIDGE, Mass., Oct. 30, 2017 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (Nasdaq:VBIV) (TSX:VBV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and...
VBI Vaccines Prices Concurrent Public Offering and Registered Direct Offering for Aggregate Proceeds of $63.5 Million
26 oct. 2017 09h29 HE
|
VBI Vaccines, Inc.
CAMBRIDGE, Mass., Oct. 26, 2017 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (Nasdaq:VBIV) (TSX:VBV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and...
VBI Vaccines Announces Proposed Concurrent Public Offering and Registered Direct Offering of Common Shares
25 oct. 2017 16h01 HE
|
VBI Vaccines, Inc.
CAMBRIDGE, Mass., Oct. 25, 2017 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (Nasdaq:VBIV) (TSX:VBV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and...
ISR's Brain Cancer (Glioblastoma Multiforme) Report Analyzes Market Opportunity, Product Pipelines
19 févr. 2014 09h59 HE
|
Industry Standard Research
CARY, NC--(Marketwired - Feb 19, 2014) - Industry Standard Research (ISR) today announced the release of a new market research report titled "Brain Cancer (Glioblastoma Multiforme): Disease and...